The Use of Low Molecular Weight Heparin in Traumatic Brain Injury
Sponsor: Aventis Pharmaceuticals
Listed as NCT00170378, this PHASE4 trial focuses on Brain Injury and Venous Thrombosis and remains completed. Sponsored by Aventis Pharmaceuticals, it has been updated 8 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE4
-
May 2019 — Apr 2020 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — May 2019 [monthly]
Completed PHASE4
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Suspended → Completed
-
Jan 2017 — Jul 2017 [monthly]
Suspended PHASE4
First recorded
Dec 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aventis Pharmaceuticals
- Hennepin Healthcare Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .